Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.
Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.
复制标题
DOI:
10.1177/1740774517752671
复制
发表时间:
2018-04
期刊:
影响因子:
--
通讯作者:
Lipsitch M
中科院分区:
文献类型:
--
作者:
Kahn R;Hitchings M;Bellan S;Lipsitch M
Network structure and individuals’ level of exposure to a pathogen can impact results from efficacy evaluation studies of interventions against infectious diseases. Heterogeneity in infection risk can cause randomized groups to increasingly differ as a trial progresses and as more high risk individuals become infected (described in prior work as the “frailty” phenomenon). Here we show the impact this phenomenon can have on an individually randomized trial of a leaky vaccine in which all participants are exchangeable a priori. We model a vaccine trial by generating a network of individuals grouped into communities, which are connected to a larger main population. We then simulate an epidemic, deterministically and with time-varying transmission rates in the main population, and stochastically in the communities. The disease natural history follows a Susceptible-Exposed-Infectious-Recovered model. Simulation results are used to estimate vaccine efficacy ( ) with a Cox proportional hazards model. We find downward bias in associated with low connectivity between communities in the study population and high force of infection, even when all participants in the trial are exchangeable at the time of randomization. This phenomenon arises because the stochastic dynamics in such a setting randomly lead to community-level variation in the force of infection. Stratifying a Cox model by community alleviates this bias with no loss of power. Understanding and accounting for the impact of heterogeneous hazard rates can allow for more accurate estimates of in epidemic settings.
登录
查看更多内容
DOI:
10.1056/nejmoa1411100
发表时间:
2014-10-16
期刊:
The New England journal of medicine
影响因子:
--
作者:
WHO Ebola Response Team;Aylward B;Barboza P;Bawo L;Bertherat E;Bilivogui P;Blake I;Brennan R;Briand S;Chakauya JM;Chitala K;Conteh RM;Cori A;Croisier A;Dangou JM;Diallo B;Donnelly CA;Dye C;Eckmanns T;Ferguson NM;Formenty P;Fuhrer C;Fukuda K;Garske T;Gasasira A;Gbanyan S;Graaff P;Heleze E;Jambai A;Jombart T;Kasolo F;Kadiobo AM;Keita S;Kertesz D;Koné M;Lane C;Markoff J;Massaquoi M;Mills H;Mulba JM;Musa E;Myhre J;Nasidi A;Nilles E;Nouvellet P;Nshimirimana D;Nuttall I;Nyenswah T;Olu O;Pendergast S;Perea W;Polonsky J;Riley S;Ronveaux O;Sakoba K;Santhana Gopala Krishnan R;Senga M;Shuaib F;Van Kerkhove MD;Vaz R;Wijekoon Kannangarage N;Yoti Z
通讯作者:
Yoti Z
影响因子:
3.1
作者:
FAUST, K;WASSERMAN, S
通讯作者:
WASSERMAN, S
影响因子:
158.5
作者:
Hadinegoro, S. R.;Arredondo-Garcia, J. L.;Saville, M.
通讯作者:
Saville, M.
影响因子:
5.4
作者:
O'Hagan, Justin J.;Lipsitch, Marc;Hernan, Miguel A.
通讯作者:
Hernan, Miguel A.
影响因子:
4.6
作者:
Staples, Patrick C.;Ogburn, Elizabeth L.;Onnela, Jukka-Pekka
通讯作者:
Onnela, Jukka-Pekka